Business
Nuwellis Announces Data Supporting Lower Heart Failure Hospitalizations and Readmissions With Aquadex
The peer-reviewed publication shows 81% lower heart failure hospitalizations per year and a 48% decrease in rehospitalizations from the national average at 30
About this update from Nuwellis, Inc.
[{"type":"text","content":"The peer-reviewed publication shows 81% lower heart failure hospitalizations per year and a 48% decrease in rehospitalizations from the national average at 30 days\nMINNEAPOLIS, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-reviewed publication of the results from a 10-year, real-world retrospective analysis of 334 hospitalized acute decompensated heart failure patients with fluid overload treated with adjustable ultrafiltration (UF) using the Aquadex FlexFlow System®. Published in the American Heart Journal Plus, the analysis conducted by investigators at Abington Hospital-Jefferson Health in Abington, Pennsylvania demonstrated significant reductions in heart failure hospitalizations and 30-day hospital readmission rates, as well as improvements in renal function response, using Aquadex ultrafiltration. The published study, titled “Ten-Year Real-World Experience with Ultrafiltration for the Management of Acute Decompensated Heart Failure,” findings included: Patients experienced an overall 81% decrease in heart failure hospitalizations per year;Rehospitalizations for patients after receiving UF with Aquadex were 48% less than the national average at 30 days (12.4% vs. 24%);55% of patients achieved sustained weight loss greater than 15 lbs.; andAll patients had stable renal function at follow-up. “We found that ultrafiltration can be used safely and effectively for significant volume removal among patients admitted with decompensated heart failure. Compared to previous trials with ultrafiltration, this real-world experience demonstrates that ultrafiltration compares favorably for weight/volume loss and renal function response, and this may be associated with a lower heart failure rehospitalization rate. We found ultrafiltration to be safe with regard to renal function, despite the cohort in this study being sicker than those studied in other clinical trials,” said Donald Haas, MD, Medical Director, Mechanical Circulatory Support and Director, Comprehensive Heart Failure Program at Abington-Jefferson Health, and Co-Investigator. “Importantly, the rate and duration of ultrafiltration was slower and longer in our study, and we believe that these considerations, combined with adjustments to the UF...